BioVendor: Archimed Acquires Leading Global Diagnostics Firm

Archimed SAS, a prominent private equity firm, has acquired BioVendor Group, a significant player in the global advanced diagnostics sector. This marks the seventh investment by Archimed's MED III fund, which amassed €650 million in 2021. The fund, now approximately half-committed, focuses on primary buyouts of small-cap healthcare companies, generally valued between €50 million and €150 million. Archimed aims to collaborate with families, founders, and management teams to boost growth. Ranked as the sixth best-performing buyout firm globally in the Dow Jones-HEC rankings, Archimed has demonstrated strong cash-to-cash returns, maintaining liquidity amidst challenging market conditions, and thus reinforcing its exceptional performance in recent years.